Alpha 2.0
Login Register
» Authors » Narukjaporn Thammajaruk

Narukjaporn Thammajaruk

Explore the profile of Narukjaporn Thammajaruk including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 179
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Pediatrics
Top 10 Co-Authors
Kiat Ruxrungtham
Anchalee Avihingsanon
Baralee Punyawudho
Torsak Bunupuradah
Jintanat Ananworanich
David M Burger
Nittaya Phanuphak
Stephen J Kerr
Stephen Kerr
Pope Kosalaraksa
Published In
J Acquir Immune Defic Syndr
AIDS Res Hum Retroviruses
J Virus Erad
Antivir Ther
J Int AIDS Soc
Affiliations
Soon will be listed here.
Recent Articles
1.
Pooled Pharyngeal, Rectal, and Urine Specimens for the Point-of-Care Detection of and by Lay Providers in Key Population-Led Health Services in Thailand
Thammajaruk N, Ramautarsing R, Hiransuthikul A, Suriwong S, Tasomboon W, Thapwong P, et al.
Pathogens . 2023 Oct; 12(10). PMID: 37887784
Routine testing for (CT) and (NG) in people with heightened risk is lacking in Thailand. This study aimed to assess the performance of the Cepheid Xpert CT/NG assay, conducted by...
2.
Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients
Singkham N, Avihingsanon A, Brundage R, Birnbaum A, Thammajaruk N, Ruxrungtham K, et al.
Expert Rev Clin Pharmacol . 2021 Nov; 15(1):99-108. PMID: 34727835
Background: This population pharmacokinetic-pharmacogenetic study aimed to investigate the optimal dose of RTV-boosted ATV (ATV/RTV) for Thai adult HIV-infected patients. Methods: A total of 1460 concentrations of ATV and RTV...
3.
Acceptability and satisfaction towards self-collection for chlamydia and gonorrhoea testing among transgender women in Tangerine Clinic, Thailand: shifting towards the new normal
Hiransuthikul A, Janamnuaysook R, Himma L, Taya C, Amatsombat T, Chumnanwet P, et al.
J Int AIDS Soc . 2021 Sep; 24(9):e25801. PMID: 34496152
Introduction: Provider-collected swabs are an unappealing procedure for many transgender women and may have led to suboptimal rates of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing. Self-collection for CT/NG...
4.
Drug-drug interactions between feminizing hormone therapy and pre-exposure prophylaxis among transgender women: the iFACT study
Hiransuthikul A, Janamnuaysook R, Himmad K, Kerr S, Thammajaruk N, Pankam T, et al.
J Int AIDS Soc . 2019 Jul; 22(7):e25338. PMID: 31298497
Introduction: Concerns over potential drug-drug interactions (DDI) between feminizing hormone therapy (FHT) and pre-exposure prophylaxis (PrEP) have hampered uptake and adherence of PrEP among transgender women (TGW). To determine DDI...
5.
Determinants of Viral Resuppression or Persistent Virologic Failure After Initial Failure With Second-Line Antiretroviral Treatment Among Asian Children and Adolescents With HIV
Teeraananchai S, Kerr S, Gandhi M, Do V, Van Nguyen L, Tran D, et al.
J Pediatric Infect Dis Soc . 2019 May; 9(2):253-256. PMID: 31125411
Of 56 children with perinatally acquired human immunodeficiency virus (HIV) who had been prescribed second-line protease inhibitor-based antiretroviral therapy and had ≥1 previous episode of viral failure (HIV RNA, ≥1000...
6.
Influence of and polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
Singkham N, Avihingsanon A, Thammajaruk N, Ruxrungtham K, Bunupuradah T, Kiertiburanakul S, et al.
Pharmacogenomics . 2019 May; 20(7):517-527. PMID: 31124411
To evaluate the influence of genetic polymorphisms on plasma trough concentrations of atazanavir (ATV) and ritonavir (RTV). The concentration-to-dose ratios were compared between different genotype groups of , ,  and...
7.
Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults
Hiransuthikul A, Thammajaruk N, Techatanawat I, Karachot B, Chuasuwan B, Manamuti C, et al.
Antivir Ther . 2018 Sep; 23(8):699-703. PMID: 30265243
Background: Ritonavir (RTV) tablets were not available in Thailand until they were manufactured by the Government Pharmaceutical Organization of Thailand. We assessed pharmacokinetics (PK), safety and efficacy of generic RTV-boosted...
8.
Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
Rungtivasuwan K, Avihingsanon A, Thammajaruk N, Mitruk S, Burger D, Ruxrungtham K, et al.
Pharmacogenomics . 2017 Oct; 18(16):1481-1490. PMID: 29061086
Aim: To develop a population pharmacokinetic model and identify sources of variability, genetic and nongenetic factors, of tenofovir. Methods: The ABCC2 and ABCC4 polymorphisms were genotyped in 342 patients. A...
9.
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents
Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, et al.
Antivir Ther . 2017 Oct; 23(3):259-265. PMID: 28994660
Background: Rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor drug, could be a favourable drug for maintenance therapy in HIV-infected adolescents because it has few long-term side effects. However, data among...
10.
Carbohydrate, lipid, bone and inflammatory markers in HIV-positive adolescents on antiretroviral therapy and hormonal contraception
Kancheva Landolt N, Bunupuradah T, Achalapong J, Kosalaraksa P, Petdachai W, Ngampiyaskul C, et al.
J Virus Erad . 2017 Mar; 3(1):56-60. PMID: 28275459
Background: Little is known about the cumulative effect of HIV antiretroviral therapy (ART) and hormonal contraception (HC) on metabolism and inflammation in HIV-positive women. Methods: We conducted a cross-sectional assessment...